Meeder Asset Management’s NextCure NXTC Stock Holding History

Meeder Asset Management’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2	Closed	–	–	2314
2020 Q2	$0	Hold	2	–	–	﹤0.01%	2322
2020 Q1	$1K	Sell	2 -4	-67%	-$2.14K	﹤0.01%	2209
2019 Q4	$3K	Buy	+6	New	+$3.01K	﹤0.01%	1932

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

CPX

Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Meeder Asset Management's NXTC Position: Q3 2020 in Review

Meeder Asset Management sold out of NextCure (NXTC) in Q3 2020, closing a stake of 2 shares.

Meeder Asset Management first reported a position in NXTC in Q4 2019 and held it in 3 quarters. The position peaked at $3K in Q4 2019. 75 funds tracked by Wall St. Rank hold NXTC as of Q3 2020.

Meeder Asset Management reported no remaining NextCure position as of Q3 2020 after selling out during the quarter.
Meeder Asset Management sold 2 NextCure shares in Q3 2020.
Meeder Asset Management first reported a position in NextCure in Q4 2019 and held it in 3 quarters.
Meeder Asset Management's NextCure position peaked at $3K in Q4 2019.
75 funds tracked by Wall St. Rank held NextCure as of Q3 2020.

Based on Meeder Asset Management's 13F filing for Q3 2020, filed 2 Nov 2020.